Cargando…

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults

New pneumococcal conjugate vaccines (PCVs), 15- and 20-valent (PCV15 and PCV20), have been licensed for use among U.S. adults based on safety and immunogenicity data compared with the previously recommended 13-valent PCV (PCV13) and 23-valent pneumococcal polysaccharide vaccines (PPSV23). We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrar, Jennifer L., Childs, Lana, Ouattara, Mahamoudou, Akhter, Fahmina, Britton, Amadea, Pilishvili, Tamara, Kobayashi, Miwako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222197/
https://www.ncbi.nlm.nih.gov/pubmed/37242402
http://dx.doi.org/10.3390/pathogens12050732
_version_ 1785049639666319360
author Farrar, Jennifer L.
Childs, Lana
Ouattara, Mahamoudou
Akhter, Fahmina
Britton, Amadea
Pilishvili, Tamara
Kobayashi, Miwako
author_facet Farrar, Jennifer L.
Childs, Lana
Ouattara, Mahamoudou
Akhter, Fahmina
Britton, Amadea
Pilishvili, Tamara
Kobayashi, Miwako
author_sort Farrar, Jennifer L.
collection PubMed
description New pneumococcal conjugate vaccines (PCVs), 15- and 20-valent (PCV15 and PCV20), have been licensed for use among U.S. adults based on safety and immunogenicity data compared with the previously recommended 13-valent PCV (PCV13) and 23-valent pneumococcal polysaccharide vaccines (PPSV23). We conducted a systematic review of the literature on PCV13 and PPSV23 efficacy (randomized controlled trials [RCTs]) or effectiveness (observational studies) against vaccine type (PCV13 type or PPSV23 type, respectively), invasive pneumococcal disease (IPD), and pneumococcal pneumonia (PP) in adults. We utilized the search strategy from a previous systematic review of the literature published during the period from January 2016 to April 2019, and updated the search through March 2022. The certainty of evidence was assessed using the Cochrane risk-of-bias 2.0 tool and the Newcastle–Ottawa scale. When feasible, meta-analyses were conducted. Of the 5085 titles identified, 19 studies were included. One RCT reported PCV13 efficacy of 75% (PCV13-type IPD) and 45% (PCV13-type PP). Three studies each reported PCV13 effectiveness against PCV13-type IPD (range 47% to 68%) and against PCV13-type PP (range 38% to 68%). The pooled PPSV23 effectiveness was 45% (95% CI: 37%, 51%) against PPSV23-type IPD (nine studies) and 18% (95% CI: −4%, 35%) against PPSV23-type PP (five studies). Despite the heterogeneity across studies, our findings suggest that PCV13 and PPSV23 protect against VT-IPD and VT-PP in adults.
format Online
Article
Text
id pubmed-10222197
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102221972023-05-28 Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults Farrar, Jennifer L. Childs, Lana Ouattara, Mahamoudou Akhter, Fahmina Britton, Amadea Pilishvili, Tamara Kobayashi, Miwako Pathogens Systematic Review New pneumococcal conjugate vaccines (PCVs), 15- and 20-valent (PCV15 and PCV20), have been licensed for use among U.S. adults based on safety and immunogenicity data compared with the previously recommended 13-valent PCV (PCV13) and 23-valent pneumococcal polysaccharide vaccines (PPSV23). We conducted a systematic review of the literature on PCV13 and PPSV23 efficacy (randomized controlled trials [RCTs]) or effectiveness (observational studies) against vaccine type (PCV13 type or PPSV23 type, respectively), invasive pneumococcal disease (IPD), and pneumococcal pneumonia (PP) in adults. We utilized the search strategy from a previous systematic review of the literature published during the period from January 2016 to April 2019, and updated the search through March 2022. The certainty of evidence was assessed using the Cochrane risk-of-bias 2.0 tool and the Newcastle–Ottawa scale. When feasible, meta-analyses were conducted. Of the 5085 titles identified, 19 studies were included. One RCT reported PCV13 efficacy of 75% (PCV13-type IPD) and 45% (PCV13-type PP). Three studies each reported PCV13 effectiveness against PCV13-type IPD (range 47% to 68%) and against PCV13-type PP (range 38% to 68%). The pooled PPSV23 effectiveness was 45% (95% CI: 37%, 51%) against PPSV23-type IPD (nine studies) and 18% (95% CI: −4%, 35%) against PPSV23-type PP (five studies). Despite the heterogeneity across studies, our findings suggest that PCV13 and PPSV23 protect against VT-IPD and VT-PP in adults. MDPI 2023-05-19 /pmc/articles/PMC10222197/ /pubmed/37242402 http://dx.doi.org/10.3390/pathogens12050732 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Farrar, Jennifer L.
Childs, Lana
Ouattara, Mahamoudou
Akhter, Fahmina
Britton, Amadea
Pilishvili, Tamara
Kobayashi, Miwako
Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title_full Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title_fullStr Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title_full_unstemmed Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title_short Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
title_sort systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222197/
https://www.ncbi.nlm.nih.gov/pubmed/37242402
http://dx.doi.org/10.3390/pathogens12050732
work_keys_str_mv AT farrarjenniferl systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT childslana systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT ouattaramahamoudou systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT akhterfahmina systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT brittonamadea systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT pilishvilitamara systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults
AT kobayashimiwako systematicreviewandmetaanalysisoftheefficacyandeffectivenessofpneumococcalvaccinesinadults